Lenvatinib Therapy for Advanced Thyroid Cancer: Real-Life Data on Safety, Efficacy, and Some Rare Side Effects
Sarah Hamidi(The University of Texas MD Anderson Cancer Center), Hortensia Mircescu(Centre Hospitalier de l’Université de Montréal), Geneviève Rondeau(Centre Hospitalier de l’Université de Montréal), Andrée Boucher(Centre Hospitalier de l’Université de Montréal), Bernard Lemieux(Centre Hospitalier de l’Université de Montréal), Xuan Kim Le(Centre Hospitalier de l’Université de Montréal), Louis‐Georges Ste‐Marie(Centre Hospitalier de l’Université de Montréal)
Cited by 22
Related Papers
Checkpoint Inhibition in Addition to Dabrafenib/Trametinib for BRAF <sup>V600E</sup> -Mutated Anaplastic Thyroid Carcinoma
|Thyroid|2024|72
Toxicity in the era of immune checkpoint inhibitor therapy
|Frontiers in Immunology|2024|56
Review article: new treatments for advanced differentiated thyroid cancers and potential mechanisms of drug resistance
|Frontiers in Endocrinology|2023|49
Initial Management of <i>BRAF </i>V600E-Variant Anaplastic Thyroid Cancer
|JAMA Oncology|2024|35
Brown tumor of the iliac crest initially misdiagnosed as a giant cell tumor of the bone
|Endocrinology Diabetes and Metabolism Case Reports|2020|20